A previous study that was divided into Part A (dose escalation) and Part B (extension) evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of the combination of eftilamidol alpha (efti, anti-LAG-3) and pembrolizumab (anti-PD-1) in patients with melanoma, and the overall response rate (ORR) was 33% in patients in Part A and 50% in patients in Part B. It was concluded that the combination of efti and pembrolizumab was well tolerated and had good antitumor activity [76]. The gene discussed is LAG3; the disease is melanoma.